WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

• Ranked among the top 1% of companies assessed in the pharmaceutical industry
• Recognized as a leader in Green CRDMO, driving innovation for a healthier future
• Committed to creating long-term value for all stakeholders

SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year the company has scored among the highest in ESG Risk Ratings.

Sustainalytics, a leading ESG data, research, and ratings firm, supports global investors with the development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings cover more than 15,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements. WuXi Biologics ranks in the top 1% of companies assessed in the pharmaceutical industry.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to once again receive this honor from Morningstar Sustainalytics. It is a reflection and recognition of our ongoing commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we consistently deliver our own ESG excellence while enabling partners worldwide to fulfill their ESG commitments, jointly working with all stakeholders to promote responsible practices throughout the entire value chain." 

In recent years, WuXi Biologics' ESG strategy and initiatives have made significant progress and gained widespread recognition. The Company was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

About Morningstar Sustainalytics

Morningstar Sustainalytics is a leading independent ESG and corporate governance research, ratings and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

SOURCE WuXi Biologics